drugset / Trial / NCT07127770

A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants

NCT07127770

Phase 1 Completed 9 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to learn how the body processes the study medicine PF-07104091. The study is seeking participants who are: \- Healthy male aged 18 to 65 years of age Participants in the study will receive 14C-labeled PF-07104091 by mouth after a meal. After 14 days, the participants will receive PF-07104091 by mouth (after a meal) followed by IV fusion (given directly into a vein) of microdose \[14C\]PF-07104091. The study will help understand how the body processes study medicine PF-07104091 and how the medicine is changed and removed from the body after you take it. This study will also help to understand how much PF-07104901 is taken up into the blood. Participants will remain in the study clinic for a maximum of 23 days and will have one follow-up contact.

Timeline

Start
2025-08-28
Primary completion
2025-10-08
Completion
2025-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject TEGTOCICLIB Small molecule Oral

Indications

No indication recorded.